| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Miravant Pharmaceuticals |
| Information provided by: | Miravant Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT00157976 |
Purpose
The purpose of this study is to confirm the efficacy and safety of rostaporfin (PHOTREX) photodynamic therapy (PDT) in the treatment of classic and occult subfoveal choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD).
| Condition | Intervention | Phase |
|
Macular Degeneration |
Drug: Photrex (rostaporfin) |
Phase III |
| Genetics Home Reference related topics: | X-linked juvenile retinoschisis |
| MedlinePlus related topics: | Macular Degeneration |
| ChemIDplus related topics: | Rostaporfin |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Efficacy Study |
| Official Title: | A Phase III Randomized, Multicenter, Multinational, Double-Masked, Placebo-Controlled Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Classic and Occult Subfoveal Choroidal Neovascularization Associated With AMD |
Eligibility
| Ages Eligible for Study: | 50 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Patients with age greater than or equal to 50 years with at least one subfoveal CNV membrane secondary to AMD that can be demonstrated by fluorescein angiography.
Contacts and Locations| Contact: Miravant Pharmaceuticals | 1-800-685-2959 | ctinfo@miravant.com |
| Bulgaria | |||||
| Multiple Investigators | Recruiting | ||||
| Sofia, Bulgaria | |||||
| Czech Republic | |||||
| Multiple Investigators | Recruiting | ||||
| Brno-Bohunice, Olomouc, Praha, Czech Republic | |||||
| Poland | |||||
| Multiple Investigators | Recruiting | ||||
| Warsaw, Bydgoszcz, Lubin, Poland | |||||
| Romania | |||||
| Multiple Investigators | Recruiting | ||||
| Bucharest, Romania | |||||
| Miravant Pharmaceuticals |
| Study Director: | Wendy J. Snyder, PhD | Miravant Pharmaceuticals |
More Information
| Study ID Numbers: | MRVT-920101-OPH005 |
| First Received: | September 8, 2005 |
| Last Updated: | November 29, 2005 |
| ClinicalTrials.gov Identifier: | NCT00157976 |
| Health Authority: | United States: Food and Drug Administration; Bulgaria: Bulgarian Drug Agency; Czech Republic: State Institute for Drug Control (SUKL); Poland: National Medicines Agency; Romania: National Medicines Agency |
|
|
|
|
|
